

## BIOSTOCK PUBLISHES AN ARTICLE DESCRIBING HOW PROLIGHT DIAGNOSTICS IS PREPARING THE CLINICAL STUDY

BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study that will form the basis for the launch of the company's high-sensitivity point of care troponin assay.

Read the full article here: <https://biostock.se/en/2025/12/prolights-cto-satter-fokus-pa-cro-partnern-mdx/>

### For further information, please contact:

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

### About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

### Attachments

**BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study**